Jan 11 |
Innate Pharma: Worth A Deeper Look
|
Jan 4 |
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
|
Jan 4 |
FDA lifts partial clinical hold on Innate Pharma's lacutamab clinical program; leadership change
|
Jan 4 |
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
|
Jan 4 |
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
|
Dec 19 |
Innate Pharma jumps 15% on licensing natural killer cell engager with Sanofi
|
Dec 19 |
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
|
Dec 18 |
Innate Pharma CEO Mahjoubi to leave company
|
Dec 18 |
Innate Pharma Announces Leadership Change
|
Dec 11 |
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
|